R365
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 101
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.440
- TGF_BETA_SIGNALING+0.420
- P53_PATHWAY+0.350
- APICAL_JUNCTION+0.310
- HYPOXIA+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
- INTERFERON_ALPHA_RESPONSE+0.290
- TNFA_SIGNALING_VIA_NFKB+0.280
- APICAL_SURFACE+0.230
- HEDGEHOG_SIGNALING+0.190
Top 10 suppressed
- E2F_TARGETS-0.610
- G2M_CHECKPOINT-0.550
- MYC_TARGETS_V1-0.330
- MYC_TARGETS_V2-0.230
- SPERMATOGENESIS-0.210
- ALLOGRAFT_REJECTION-0.200
- MTORC1_SIGNALING-0.180
- MITOTIC_SPINDLE-0.170
- OXIDATIVE_PHOSPHORYLATION-0.170
- PEROXISOME-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2932823 | — | — | 0.860 |
| 2 | TCGA-FD-A3SQ-01A-21R-A22U-07 | — | — | 0.841 |
| 3 | 1af0bfa7-8beb-499f-a658-ed1dd9fdb701 | — | — | 0.835 |
| 4 | R66 | — | — | 0.818 |
| 5 | JHH2_LIVER | HCC | — | 0.812 |
| 6 | TCGA-E2-A153-01A-12R-A12D-07 | — | A | 0.811 |
| 7 | b65a6759-a9a4-4740-a9e3-962771dd9954 | — | — | 0.800 |
| 8 | SRR13311162 | — | — | 0.796 |
| 9 | SRR6013577 | — | cohortA1 | 0.785 |
| 10 | TCGA-A1-A0SD-01A-11R-A115-07 | — | A | 0.782 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.350 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.280 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.160 | Idelalisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |